A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System (STRIDES)

A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions

The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal lesions.

Abbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The decision to discontinue the study is not related to any safety concern. The rationale for this proposal is based on the following considerations:

The performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and no stent fractures, and the rate of additional revascularizations has been stable since approximately 14 months after the procedure.

Evaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature show low rates of death, reintervention and stent fracture, which are consistent with STRIDES and demonstrate the safety of the nitinol stent platform of the DYNALINK-E.

Long-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E - everolimus tissue concentration drops below the quantifiable limit by approximately 17 months after implant, and vascular response to the coating is normal with widely patent lumens and struts incorporated into vessel tissue.

The safety and performance of the DYNALINK-E has been substantiated by its clinical and pre-clinical data, and by the clinical data of similar products. Given the demonstrated mechanical integrity of the stent along with the evidence of a healthy long-term vascular response, there is a reasonable expectation of continued low event rates.

Study Overview

• Status: Completed
• Conditions: Atherosclerosis; Peripheral Vascular Disease
• Intervention / Treatment: Device: Dynalink®-E everolimus-eluting peripheral stent; Device: Dynalink®-E, everolimus-eluting peripheral stent

Detailed Description

A prospective, Non-Randomized, Single-arm, Multi-center, Clinical Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for the Treatment of Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions.

• Study Type: Interventional
• Enrollment (Actual): 104
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Austria
  • Klagenfurt, Austria, 9020
    • Landeskrankenhaus Klagenfurt
  • Wien, Austria, 1090
    • Allgemeines Krankenhaus der Stadt Wien- AKH Wien
• Belgium
  • Dendermonde, Belgium
    • Sint Blasius Hospital
  • Gent, Belgium, 3600
    • ZOL St. jan
  • Gent, Belgium, 9000
    • University Hospital
• Germany
  • Bad Krozingen, Germany, 79189
    • Herzzentrum Bad Krozingen
  • Berlin, Germany, 13347
    • The Jewish Hospital Berlin
  • Leipzig, Germany, 04289
    • Herzzentrum Leipzig
  • Tübingen, Germany, 72076
    • University Hospital Tübingen
• Italy
  • Mercogliano, Italy, 83013
    • Casa di Cura di Montevergine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Rutherford Becker Category 2-5
• Single de novo or restenotic lesion in the superficial femoral or proximal popliteal artery
• Disease segment length 30-170 mm
• >50% diameter stenosis or total occlusion
• Target reference vessel diameter 4.3-7.3 mm

Exclusion Criteria:

• Target lesion previously treated with stent or surgery
• Rutherford Becker Category 0, 1, or 6
• Immunosuppressive disorder or currently receiving immunosuppressive agents
• Serum creatinine >2.5 mg/dl

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: 1; This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.

Device: Dynalink®-E everolimus-eluting peripheral stent; Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery; Device: Dynalink®-E, everolimus-eluting peripheral stent; Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
In-stent binary restenosis (>50% stenosis), as measured by duplex ultrasound	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Angiographic in-stent binary restenosis rate (>50%)	12 months
Angiographic mean in-stent late loss, in-stent mean minimum lumen diameter (MLD), percent diameter stenosis	12 months
Primary, and secondary patency	1, 6, 12, 18 months, 2, 3, 4, 5 years

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Principal Investigator: Johannes Lammer, M.D., Allgemeines Krankenhaus der Stadt Wien

Publications and helpful links

General Publications

• Lammer J, Scheinert D, Vermassen F, Koppensteiner R, Hausegger KA, Schroe H, Menon RM, Schwartz LB. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. J Vasc Surg. 2012 Feb;55(2):400-5. doi: 10.1016/j.jvs.2011.08.048. Epub 2011 Nov 1.
• Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011 Aug;54(2):394-401. doi: 10.1016/j.jvs.2011.01.047. Epub 2011 Jun 12.

Study record dates

Study Major Dates

• Study Start: May 1, 2007
• Primary Completion (Actual): July 1, 2008
• Study Completion (Actual): February 1, 2010

Study Registration Dates

• First Submitted: May 16, 2007
• First Submitted That Met QC Criteria: May 16, 2007
• First Posted (Estimate): May 21, 2007

Study Record Updates

• Last Update Posted (Estimate): March 10, 2011
• Last Update Submitted That Met QC Criteria: March 9, 2011
• Last Verified: March 1, 2011

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Peripheral Arterial Disease; Peripheral Vascular Diseases; Atherosclerosis; Physiological Effects of Drugs; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Everolimus
• Other Study ID Numbers: 06-103